Conoa-B (02162): Phase III clinical trial of spoxibimab injection to treat seasonal allergic rhinitis reached the main end
Conoa-B (02162) issued an announcement. The company is pleased to announce that its Class 1 new drug, CM310, recombinant humanized monogram...
康諾亞-B:2023年度報告
Subdued Growth No Barrier To Keymed Biosciences Inc.'s (HKG:2162) Price
With a price-to-sales (or "P/S") ratio of 23.3x Keymed Biosciences Inc. (HKG:2162) may be sending very bearish signals at the moment, given that almost half of all the Biotechs companies in Hong Kong
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 6%, CM310 has submitted a listing application, and the company is welcoming the new commercialization cycle
Conoa-B (02162) rose more than 6%. As of press release, it had risen 6.17% to HK$30.95, with a turnover of HK$8.98,800.
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 7% in the afternoon to complete a clinical trial of a drug to treat advanced solid tumors, completed the first case of the first test subject
Conoa-B (02162) rose more than 7% in the afternoon. As of press release, it was up 6.74% to HK$29.3, with a turnover of HK$404.85,500.
[Broker Focus] Changjiang Securities maintains Conoa-B (02162) “buy” rating, indicating that the smooth progress of its pipeline will welcome a new commercialization cycle
Jinwu Financial News | According to Changjiang Securities Research, the Conoa-B (02162) performance report shows that the company achieved operating income of 354 million yuan for the full year of 2023, mainly including cooperative revenue generated from licensing to AZ; loss of 318 million yuan during the adjusted year of 2023 (loss of 255 million yuan last year), and R&D expenses for the full year of 2023 were 596 million yuan (507 million yuan in 2022). According to the bank, the company's core product, CM310, has submitted a marketing application, and the indications continue to expand to open up the growth ceiling. CM310 is the fastest domestically produced IL-4Rα developed by the company
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study
Keymed Biosciences (HKG:2162) said the first subject received the first dose of its advanced solid tumors drug on Thursday, according to a Friday Hong Kong bourse filing. Keymed Biosciences signed a d
Conoa-B (02162.HK): Renewed license agreement with ASTRAZENECA for CMG901 (AZD0901)
On April 12, GLONGHUI | Conoa-B (02162.HK) released an update on the licensing agreement between KYM Biosciences Inc. (“KYM”, a 70% non-wholly-owned subsidiary of the Group) and AstraZeneca AB (“AstraZeneca”, a global biopharmaceutical company) for the company's pipeline product CMG901 (AZD0901). In February 2023, KYM signed an exclusive global license agreement with AstraZeneca to develop and commercialize CMG901
Keymed Biosciences Inc. (HKG:2162) Just Reported, And Analysts Assigned A HK$69.56 Price Target
Shareholders might have noticed that Keymed Biosciences Inc. (HKG:2162) filed its annual result this time last week. The early response was not positive, with shares down 6.6% to HK$33.90 in the past
Changes in Hong Kong stocks | Conoa-B (02162) rose more than 7% in the intraday period, annual revenue increased 2.5 times, and CM310 is expected to be approved for listing within the year
Conoa-B (02162) rose more than 7% in the intraday period. As of press release, it was up 5.11% to HK$3.39, with a turnover of HK$396.561 million.
Retail Investors Among Keymed Biosciences Inc.'s (HKG:2162) Largest Stockholders and Were Hit After Last Week's 14% Price Drop
Key Insights Significant control over Keymed Biosciences by retail investors implies that the general public has more power to influence management and governance-related decisions The top 8 shareho
KeyMed Biosciences' Attributable Loss Widens in 2023
KeyMed Biosciences (HKG:2162) widened its attributable loss to owners for the year ended Dec. 31, 2023, to 359.3 million yuan, compared with 308.1 million yuan in the year-ago period, according to a f
Conoah Announces 2023 Results: Deepening Differential Innovation and Ready to Start Commercialization
The drug marketing license application (NDA) for the treatment of moderate to severe atopic dermatitis in adults (CM310), a core product in the field of autoimmunity, has been accepted by the China Drug Administration and included in the priority review and approval process; the phase III clinical study data on the treatment of chronic sinusitis with nasal polyps were positive, and the common main endpoints were fully met. It is expected that NDA for this indication will be declared in 2024; at the same time, the use of sipcibimab for the treatment of moderate and severe atopic dermatitis in adolescents will be launched and promoted separately Seasonal allergic rhinitis Phase III clinical study; in situ
Press Release: Keymed Biosciences Announces 2023 Annual Results and Business Updates
Keymed Biosciences Announces 2023 Annual Results and Business Updates PR Newswire CHENGDU, China, March 26, 2024 -- Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the tr
Conoa-B (02162) announced annual results. After adjustment, loss of 318 million yuan during the year increased 25% year-on-year
Conoa-B (02162) announced results for the year ended December 31, 2023. The group received revenue...
KEYMED BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY
Conoa-B (02162.HK) will hold a board meeting on March 26 to approve the full year results
Glonghui March 14 | Conoa-B (02162.HK) announced that the company will hold a board meeting on March 26, 2024 to review and approve the annual results and publication of the company and its subsidiaries for the year ended December 31, 2023, and to consider the payment of a final dividend (if any).
KEYMED BIO-B: DATE OF BOARD MEETING
No Data